<table>
<thead>
<tr>
<th>APPLICATION NO.</th>
<th>FILING DATE</th>
<th>FIRST NAMED INVENTOR</th>
<th>ATTORNEY DOCKET NO.</th>
<th>CONFIRMATION NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/071,499</td>
<td>02/08/2002</td>
<td>Neil M. Wolfman</td>
<td>8702.0100-00</td>
<td>3454</td>
</tr>
</tbody>
</table>

7590          08/23/2006

c/o Rebecca M. McNeill
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.
1300 I Street, N.W.
Washington, DC 20005-3315

Please find below and/or attached an Office communication concerning this application or proceeding.
Advisory Action
Before the Filing of an Appeal Brief

Application No. 10/071,499
Applicant(s) WOLFMAN ET AL.
Examiner Cherie M. Woodward
Art Unit 1647

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

THE REPLY FILED 10 August 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. ☒ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:
   a) ☒ The reply period expires 3 months from the mailing date of the final rejection.
   b) ☐ The reply period expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 709.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☐ The Notice of Appeal was filed on . A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(e)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. ☒ The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
   a) ☒ They raise new issues that would require further consideration and/or search (see NOTE below);
   b) ☐ They raise the issue of new matter (see NOTE below);
   c) ☒ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
   d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)).

4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5. ☐ Applicant's reply has overcome the following rejection(s): ________

6. ☒ Newly proposed or amended claim(s) 119-132 would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. ☒ For purposes of appeal, the proposed amendment(s): a) ☒ will not be entered, or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: ________
Claim(s) objected to: ________
Claim(s) rejected: 119-132 and 144-173
Claim(s) withdrawn from consideration: 33-35, 38, 42-48, 50-59, and 137-142.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9. ☐ The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing of good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. ☐ The request for reconsideration has been considered but does NOT place the application in condition for allowance because: ________

12. ☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). ________

13. ☐ Other: ________

U.S. Patent and Trademark Office
PTOL-303 (Rev. 7-05) Advisory Action Before the Filing of an Appeal Brief Part of Paper No. 20060819
MMarine Allen
8/2/06
Continuation of 3. NOTE: It is noted that the amendments to claims 119-132, 144-152, and 160-173 attempt to narrow the scope of the claims in terms of percent identity and in terms of undescribed fragments. Claims 119-132 would be allowable as amended, if entered. However, claims 144-152 and 160-173 continue to read on fragments that are not adequately described in the specification. The open-ended language of claim 144, which recites "A GDF-8 propeptide that has been modified at the aspartate residue corresponding to ASP76 of SEQ ID NO: 5 comprising a GDF-8 moiety comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 5 wherein..." The GDF-8 propeptide modified at ASP76 comprising a GDF-8 moiety comprising the amino acid sequence that is 95% identical to SEQ ID NO: 5 reads on a fragment. The concern is raised because of Applicant's non-limiting definition of GDF-8 on page 7 of the specification and the use of the term "GDF-8 moiety" in the claims. As such, it appears that the claims still read on fragments that are not fully enabled nor adequately described by the disclosure. Similarly, the disclosure is not fully enabling for new claims 174-182. The new claims also raise issues of indefiniteness that would require further consideration. Because the entry of the claim amendments after final must be done for all or none of the claims, entry is denied for the aforementioned reasons. Applicant is invited to file a Request for Continuing Examination if they wish to have the claim amendments entered and the new claims fully examined.

CMW Art Unit 1647